ACRONYM

TESAR

A Multi-centre randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer

Laboratory technician using a telescope

Study information

Principal Investigators:

Dr. J.B. Tuynman

Amsterdam UMC

Location VU Medical Center

De Boelelaan 1117

1007 MB Amsterdam

Location ZH 7F 20

 

 

Trial coordinator:

Laura Moolenaar

l.r.moolenaar@amsterdamumc.nl

tesartrial@amsterdamumc.nl

www.tesartrial.nl

In this multicentre randomised trial, patients with an intermediate risk T1-2 rectal cancer, that has been locally excised using an endoluminal technique, will be randomised between adjuvant chemo-radiotherapy limited to the mesorectum and standard completion total mesorectal excision (TME). To strictly monitor the risk of locoregional recurrence in the experimental arm and enable early salvage surgery, there will be additional follow up with frequent MRI and endoscopy. The primary outcome of the study is three-year local recurrence rate. Secondary outcomes are morbidity, disease free and overall survival, stoma rate, functional outcomes, health related quality of life and costs. The design is a non-inferiority study with a total sample size of 302 patients .

Arm A

Completion TME

Arm B

Adjuvant chemoradiotherapy (25×1.8 Gy + Capecitabine)

Documents

Subscribe to our newsletter

Realisatie door Webfresh

Privacy Policy
© dccg.nl